-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
ZIVO Bioscience (OTCMKTS:ZIVO) Share Price Passes Below 50-Day Moving Average of $3.65
ZIVO Bioscience (OTCMKTS:ZIVO) Share Price Passes Below 50-Day Moving Average of $3.65
ZIVO Bioscience, Inc. (OTCMKTS:ZIVO – Get Rating) passed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $3.65 and traded as low as $2.85. ZIVO Bioscience shares last traded at $3.02, with a volume of 6,150 shares traded.
ZIVO Bioscience Price Performance
The business's 50-day moving average price is $3.62 and its two-hundred day moving average price is $3.55. The company has a market capitalization of $26.38 million, a P/E ratio of -2.83 and a beta of -0.05.
Get ZIVO Bioscience alerts:ZIVO Bioscience (OTCMKTS:ZIVO – Get Rating) last issued its quarterly earnings data on Thursday, August 4th. The biotechnology company reported ($0.22) EPS for the quarter.
Insider Transactions at ZIVO Bioscience
In other ZIVO Bioscience news, Director Christopher D. Maggiore bought 7,200 shares of the firm's stock in a transaction that occurred on Wednesday, September 14th. The shares were acquired at an average cost of $3.53 per share, with a total value of $25,416.00. Following the acquisition, the director now owns 810,305 shares of the company's stock, valued at $2,860,376.65. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 9.10% of the company's stock.Institutional Investors Weigh In On ZIVO Bioscience
A hedge fund recently raised its stake in ZIVO Bioscience stock. Vanguard Group Inc. grew its position in ZIVO Bioscience, Inc. (OTCMKTS:ZIVO – Get Rating) by 19.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 92,468 shares of the biotechnology company's stock after purchasing an additional 15,147 shares during the quarter. Vanguard Group Inc. owned approximately 0.98% of ZIVO Bioscience worth $359,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 5.04% of the company's stock.
About ZIVO Bioscience
(Get Rating)
ZIVO Bioscience, Inc, a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. It operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health.
See Also
- Get a free copy of the StockNews.com research report on ZIVO Bioscience (ZIVO)
- 2 Casino Stocks Worth Taking a Look At
- This Small-Cap Healthcare Name Is Outperforming Its Index
- What Cintas Can Teach Investors About This Bear Market?
- Blackberry Stock Declines As Results Come In Lukewarm Once Again
- A Trio of Q3 Winners With Room to Run
Receive News & Ratings for ZIVO Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIVO Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
ZIVO Bioscience, Inc. (OTCMKTS:ZIVO – Get Rating) passed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $3.65 and traded as low as $2.85. ZIVO Bioscience shares last traded at $3.02, with a volume of 6,150 shares traded.
Zivo Bioscience，Inc.(场外交易市场代码：Zivo-GET评级)在周二的交易中跌破了50日移动均线。该股的50日移动均线为3.65美元，最低交易价格为2.85美元。Zivo Bioscience的股票最新报3.02美元，成交量为6,150股。
ZIVO Bioscience Price Performance
Zivo生物科学性价比
The business's 50-day moving average price is $3.62 and its two-hundred day moving average price is $3.55. The company has a market capitalization of $26.38 million, a P/E ratio of -2.83 and a beta of -0.05.
该业务的50日移动均线价格为3.62美元，200日移动均线价格为3.55美元。该公司市值为2,638万美元，市盈率为-2.83，贝塔系数为-0.05。
ZIVO Bioscience (OTCMKTS:ZIVO – Get Rating) last issued its quarterly earnings data on Thursday, August 4th. The biotechnology company reported ($0.22) EPS for the quarter.
Zivo Bioscience(OTCMKTS：ZIVO-GET Rating)最近一次发布季度收益数据是在8月4日星期四。这家生物技术公司公布了本季度每股收益(0.22美元)。
Insider Transactions at ZIVO Bioscience
Zivo Bioscience的内幕交易
Institutional Investors Weigh In On ZIVO Bioscience
机构投资者看好Zivo生物科学
A hedge fund recently raised its stake in ZIVO Bioscience stock. Vanguard Group Inc. grew its position in ZIVO Bioscience, Inc. (OTCMKTS:ZIVO – Get Rating) by 19.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 92,468 shares of the biotechnology company's stock after purchasing an additional 15,147 shares during the quarter. Vanguard Group Inc. owned approximately 0.98% of ZIVO Bioscience worth $359,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 5.04% of the company's stock.
一家对冲基金最近增持了Zivo Bioscience股票。先锋集团(Vanguard Group Inc.)在最近提交给美国证券交易委员会的13F文件中称，今年第一季度，该公司在Zivo Bioscience，Inc.(场外交易代码：Zivo-GET评级)的持仓增加了19.6%。该基金在本季度额外购买了15,147股后，持有这家生物技术公司的92,468股股票。截至最近提交给美国证券交易委员会的文件，先锋集团持有Zivo Bioscience约0.98%的股份，价值35.9万美元。机构投资者和对冲基金持有该公司5.04%的股票。
About ZIVO Bioscience
关于Zivo生物科学
(Get Rating)
(获取评级)
ZIVO Bioscience, Inc, a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. It operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health.
Zivo Bioscience，Inc.是一家研发公司，致力于向动物、人类、膳食补充剂和医用食品制造商许可和销售从其专有藻类培养物中提取的天然生物活性成分。它在生物技术和农业技术部门开展业务，拥有知识产权组合，包括专有藻类和细菌菌株、生物活性分子和复合体、生产技术、栽培技术，以及应用于人类和动物健康的专利或正在申请专利的发明。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on ZIVO Bioscience (ZIVO)
- 2 Casino Stocks Worth Taking a Look At
- This Small-Cap Healthcare Name Is Outperforming Its Index
- What Cintas Can Teach Investors About This Bear Market?
- Blackberry Stock Declines As Results Come In Lukewarm Once Again
- A Trio of Q3 Winners With Room to Run
- 免费获取StockNews.com关于Zivo生物科学的研究报告(Zivo)
- 值得一看的2只赌场股票
- 这家小盘股医疗保健公司的表现好于其指数
- 关于这个熊市，Cintas能教给投资者什么？
- 黑莓股价下跌，业绩再次不温不火
- 第三季度赢家三人组还有运行的空间
Receive News & Ratings for ZIVO Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIVO Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
获得Zivo生物科学日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Zivo Bioscience和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧